Description
About Epbriv 0.88 mg Injection
Epbriv 0.88 mg Injection contains 0.88 mg of eribulin mesylate in a single vial. Eribulin is a cytotoxic chemotherapy medicine — a non-taxane inhibitor of microtubule dynamics — given as an intravenous injection by a doctor or nurse under the supervision of a cancer specialist.
How it works
Before a cell can divide it must build a scaffold of microtubules to pull its chromosomes apart. Eribulin binds to the growing ends of those microtubules and stops them lengthening, so the scaffold never forms properly. The cell stalls part-way through division and dies. It acts at a different point from the taxanes, which is why it can still work after them.
What it is used for
Eribulin is used in locally advanced or metastatic breast cancer in people who have already had other chemotherapy, and in advanced or inoperable liposarcoma after treatment containing an anthracycline.
Important: this is not a neurological medicine
Eribulin does not treat epilepsy, nerve pain or any other neurological condition. Nerve damage is a recognised side effect of eribulin, not something it is given for.
Safety and monitoring
The most common serious effect is a fall in white blood cells, so blood counts are checked before each dose and any fever or sign of infection needs urgent attention. Numbness, tingling or weakness in the hands and feet can develop and should be reported early, as the dose can be adjusted. Tiredness, nausea, constipation and hair loss are common. Eribulin can affect the heart rhythm, so tell your doctor about heart problems, and about any other medicines you take. Liver and kidney function are monitored.
Prescription and storage
A prescription is required, and treatment is given under the supervision of a cancer specialist. Storage and handling follow the pack instructions and are managed by the treating centre.
Reviews
There are no reviews yet.